Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. This thesis established: the accuracy of two non-invasive fibrosis tests to predict advanced fibrosis in NAFLD patients; that the presence of type 2 diabetes in NAFLD compensated cirrhosis patients increase mortality, hepatic decompensation and hepatocellular carcinoma, and that continuous use of metformin in NAFLD cirrhosis patients with type 2 diabetes is associated with improved clinical outcomes. Two prognostic scores that accurately predict hepatic decompensation in NAFLD patients and in those with NAFLD compensated liver cirrhosis were also developed and presented in this thesis.
| Original language | English |
|---|---|
| Qualification | Doctor of Philosophy |
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Thesis sponsors | |
| Award date | 21 Jul 2022 |
| DOIs | |
| Publication status | Unpublished - 2022 |
Access to Document
- THESIS - DOCTOR OF PHILOSOPHY - CALZADILLA BERTOT, Luis - 2022
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.